Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of NANO-efavirenz and NANO-lopinavir in Healthy Volunteers
NCT02631473Phase 1Suspended
- Sponsor
- St Stephen's AIDS Trust
- Start
- Nov 2015
- Primary completion
- Nov 2017
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of efavirenz nanoparticles and NANO-Lopinavir in human immunodeficiency virus infection (HIV) (6 arms), sponsored by St Stephen's AIDS Trust. Primary endpoints: Trough Concentration at Day 80, Maximum Plasma Concentration at Day 80 and 3 more. Started Nov 2015; status: suspended.
02
Drugs
efavirenz nanoparticlesNANO-Lopinavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02631473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02631473.